Columbia Financial Inc (CLBK)

John Klimowich, SEVP and Chief Risk Officer at Columbia Financial, acquired 58.0679 phantom stock units on August 21, 2026, at $11.79 each through the Columbia Bank Stock Based Deferral Plan. This non-discretionary acquisition adds to his substantial holdings, which include direct stock ownership, various indirect holdings through different plans, and numerous stock options. The filing provides a comprehensive overview of Klimowich's beneficial ownership in Columbia Financial (NASDAQ:CLBK).

John Klimowich, SEVP & Chief Risk Officer of Columbia Financial, Inc. (CLBK), received an award of 58.0679 shares of Common Stock at $11.79 per share on August 21, 2026. These shares were credited as phantom stock within a stock-based deferral plan, increasing his indirect holdings in that plan to 20,522.7185 shares. The filing also details his direct holdings of 145,056 Common shares and various stock option positions.

Columbia Financial (CLBK) CEO Thomas J. Kemly received an award of 157.5649 shares of Common Stock on August 21, 2026, under a stock-based deferral plan, valued at $11.79 per share. This transaction increases his indirect holdings in the Columbia Bank Stock Based Deferral Plan to 153,816.4041 shares, settled as phantom stock. The filing also details Kemly's substantial direct and indirect Common Stock holdings and various outstanding stock options with exercise prices ranging from $7.10 to $8.31 per share.

Columbia Financial, Inc. has initiated a firm commitment underwritten offering to sell between $281 million and $769 million of common stock at $10.00 per share, following a successful subscription offering that raised approximately $1.1 billion. This offering aims to sell shares not subscribed for in its second-step conversion subscription offering. The completion of this conversion is contingent on regulatory approvals, an independent appraisal, and the sale of at least 142,375,000 shares.

Keefe, Bruyette & Woods has upgraded Columbia Financial (NASDAQ:CLBK) to a "moderate buy" rating, joining other analysts who have also recently raised their ratings. The stock currently holds a "Moderate Buy" consensus with a target price of $15.10. Institutional investors have significantly increased their positions in CLBK, with BlackRock acquiring a new $51.9 million position and Marshall Wace increasing its holdings by 297.5%.